View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 5, 2020updated 12 Jul 2022 11:48am

Gilead reports positive data from filgotinib’s Phase III trials

Gilead Sciences and Galapagos have reported positive data from the Phase III FINCH 1 and FINCH 3 clinical trials of filgotinib in adults with moderately to severely active rheumatoid arthritis (RA). 

Gilead Sciences and Galapagos have reported positive data from the Phase III FINCH 1 and FINCH 3 clinical trials of filgotinib in adults with moderately to severely active rheumatoid arthritis (RA).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Results showed sustained efficacy and a consistent safety profile up to 52 weeks.

The FINCH 1 study compared filgotinib to placebo or adalimumab on a stable background methotrexate dose in patients who previously experienced an inadequate response to methotrexate.

Patients received filgotinib 200mg once daily, 100mg once daily, adalimumab 40mg bi-weekly, or matching placebo.

Data demonstrated that filgotinib 200mg met the primary study endpoint with a higher proportion of patients achieving at least a 20% improvement in the number of tender and swollen joints at week 12 compared to placebo.

The drug was also superior to placebo on all secondary endpoints of signs and symptoms of RA, physical function, and structural damage.

At 52 weeks, both doses of the drug demonstrated sustained efficacy in primary and secondary outcome measures. The safety profile was also consistent, without any new signals through week 52.

Meanwhile, the FINCH III trial assessed filgotinib in patients naïve to methotrexate.

Patients received filgotinib 200mg plus methotrexate, filgotinib 100mg plus methotrexate, filgotinib 200mg monotherapy and methotrexate monotherapy.

This study also met the primary study endpoint of the proportion of patients achieving ACR20 at week 24 compared to methotrexate alone. All treatment groups showed sustained efficacy to week 52, Gilead added.

Gilead Sciences Inflammation senior vice-president Mark Genovese said: “Many people with RA struggle with uncontrolled symptoms that affect their daily lives. We are working to develop effective and well-tolerated treatment options that will make a difference in the lives of patients.

“These data add to the body of evidence supporting filgotinib as a potential treatment option for a range of RA patients.”

Gilead and Galapagos partnered for the global development and commercialisation of filgotinib in RA and other inflammatory indications.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena